ArticleAmerican journal of cancer research2020

Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study.

Feng Wang et al.PubMed ↗Full text ↗

No numbers read from the abstract.